SunTrust Downgrades Sarepta Therapeutic (SRPT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Sarepta Therapeutic (SRPT) PT Bumped to $35 at RBC Capital
August 7, 2015 8:21 AM EDTRBC Capital analyst Simos Simeonidis reiterated a Sector Perform rating and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $35.00 (from $20.00) to account for the potential value of eteplirsen's follow-on exon programs.
Simeonidis commented, "Sarepta updated investors on the progress of... More
Sarepta Therapeutic (SRPT) PT Raised to $47 at Baird; Increasingly Bullish on Risk/Reward
August 7, 2015 7:41 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $47.00 (from $34.00), saying they are increasingly bullish on risk/reward.
Sarepta commented, "After spending time with management recently and hearing additional granularity on the... More
Sarepta Therapeutics (SRPT) Tops Q2 EPS by 20c
August 6, 2015 7:35 AM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.01), $0.20 better than the analyst estimate of ($1.21).
We made significant achievements from both a regulatory and clinical perspective this quarter and look to build on this momentum as we continue through the regulatory process for eteplirsen,... More
